- Home
- VMO vs NRIX Comparison
VMO vs NRIX Comparison
Compare VMO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMO
- NRIX
- Stock Information
- Founded
- VMO 1992
- NRIX 2009
- Country
- VMO United States
- NRIX United States
- Employees
- VMO N/A
- NRIX N/A
- Industry
- VMO Trusts Except Educational Religious and Charitable
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- VMO Finance
- NRIX Health Care
- Exchange
- VMO Nasdaq
- NRIX Nasdaq
- Market Cap
- VMO 608.3M
- NRIX 728.6M
- IPO Year
- VMO N/A
- NRIX 2020
- Fundamental
- Price
- VMO $9.22
- NRIX $9.33
- Analyst Decision
- VMO
- NRIX Strong Buy
- Analyst Count
- VMO 0
- NRIX 15
- Target Price
- VMO N/A
- NRIX $29.13
- AVG Volume (30 Days)
- VMO 254.7K
- NRIX 607.0K
- Earning Date
- VMO 01-01-0001
- NRIX 10-10-2025
- Dividend Yield
- VMO 4.39%
- NRIX N/A
- EPS Growth
- VMO N/A
- NRIX N/A
- EPS
- VMO N/A
- NRIX N/A
- Revenue
- VMO N/A
- NRIX $88,381,000.00
- Revenue This Year
- VMO N/A
- NRIX $74.59
- Revenue Next Year
- VMO N/A
- NRIX N/A
- P/E Ratio
- VMO N/A
- NRIX N/A
- Revenue Growth
- VMO N/A
- NRIX 41.86
- 52 Week Low
- VMO $7.86
- NRIX $8.18
- 52 Week High
- VMO $9.87
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- VMO 56.11
- NRIX 36.44
- Support Level
- VMO $9.21
- NRIX $9.31
- Resistance Level
- VMO $9.27
- NRIX $10.33
- Average True Range (ATR)
- VMO 0.06
- NRIX 0.51
- MACD
- VMO 0.00
- NRIX -0.02
- Stochastic Oscillator
- VMO 68.18
- NRIX 9.12
About VMO Invesco Municipal Opportunity Trust
Invesco Municipal Opportunity Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.